Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation. | ACS Chem Biol | 2024 | 38305738 | PubTator, text mining | PubMed |
| Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. | iScience | 2024 | 38303720 | PubTator, text mining | PubMed |
| Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance. | Hematol Oncol Clin North Am | 2024 | 38302306 | PubTator, text mining | PubMed |
| Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. | J Med Chem | 2024 | 38300987 | PubTator, text mining | PubMed |
| Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview. | Front Immunol | 2024 | 38298192 | PubTator, text mining | PubMed |
| The Development and Application of Biophysical Assays for Evaluating Ternary Complex Formation Induced by Proteolysis Targeting Chimeras (PROTACS). | J Vis Exp | 2024 | 38284532 | PubTator, text mining | PubMed |
| Functional Analysis of KAP1/TRIM28 Requirements for HIV-1 Transcription Activation. | Viruses | 2024 | 38257816 | PubTator, text mining | PubMed |
| From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation. | Pharmaceuticals (Basel) | 2024 | 38256933 | PubTator, text mining | PubMed |
| Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review. | Int J Mol Sci | 2024 | 38255778 | PubTator, text mining | PubMed |
| Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update. | Biomedicines | 2024 | 38255243 | PubTator, text mining | PubMed |
| Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species. | Cells | 2024 | 38247866 | PubTator, text mining | PubMed |
| Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. | EBioMedicine | 2024 | 38244292 | PubTator, text mining | PubMed |
| LINC00571 drives tricarboxylic acid cycle metabolism in triple-negative breast cancer through HNRNPK/ILF2/IDH2 axis. | J Exp Clin Cancer Res | 2024 | 38238853 | PubTator, text mining | PubMed |
| MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3. | ACS Med Chem Lett | 2024 | 38229760 | PubTator, text mining | PubMed |
| DegraderTCM: A Computationally Sparing Approach for Predicting Ternary Degradation Complexes. | ACS Med Chem Lett | 2024 | 38229751 | PubTator, text mining | PubMed |
| Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. | Nat Commun | 2024 | 38228616 | PubTator, text mining | PubMed |
| Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth. | Mol Cancer Ther | 2024 | 38224565 | PubTator, text mining | PubMed |
| Degradation by Design: New Cyclin K Degraders from Old CDK Inhibitors. | ACS Chem Biol | 2024 | 38193430 | PubTator, text mining | PubMed |
| Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1. | ACS Chem Biol | 2024 | 38192078 | PubTator, text mining | PubMed |
| A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα. | Chem Sci | 2024 | 38179525 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=23